NEW YORK, March 29, 2026, 12:07 EDT
- CSL Limited’s U.S.-traded shares ended Friday at $24.34, up 1.16%. 1
- CSL’s latest buyback filing showed 89,271 shares repurchased on March 26, taking the total to about 5.18 million. 2
- The market is still weighing February’s 81% first-half profit drop and management’s decision to hold full-year guidance. 3
CSL Limited’s American depositary receipts, the U.S.-traded form of its shares, ended Friday up 1.16% at $24.34, a modest sign of stability for the Australian biotech after weeks of pressure tied to weak earnings and leadership change. 1
That matters because CSL is not a fringe stock. It is one of Australia’s largest healthcare names, and confidence in the group has been hit since February, when it posted an 81% drop in first-half reported profit, widened its buyback to US$750 million and installed Gordon Naylor as interim chief after Paul McKenzie retired. 3
The company spans plasma therapies, influenza vaccines, and kidney and iron drugs. Its plasma network runs through roughly 325 collection centres in the United States, Europe and China, so any wobble in execution tends to show up fast in sentiment and in the stock. 4
In its latest disclosed buyback update, CSL said it bought back 89,271 shares on March 26 for A$12.81 million. The filing showed 5,180,698 shares repurchased in total for about A$900.4 million under an on-market buyback, meaning purchases made through the exchange, with the program set to run until June 30. 2
When CSL released its half-year results, Chief Financial Officer Ken Lim said the group was “clearly not satisfied with our performance” and had “an ambitious growth plan” for the second half, led by immunoglobulin, a plasma-based immune therapy, albumin and newer product launches.
Naylor struck much the same line. He told analysts he was “not prepared to accept” that the company could not do better, even as he described the U.S. vaccine market as “extraordinarily difficult”. David Tuckwell, chief investment officer at ETF Shares, said Naylor’s return looked like “an attempt to calm nerves” and possibly “a salvage mission”. 3
But the risks are still plain. CSL has said Seqirus will contribute less in the second half because flu vaccine sales are seasonal and last year’s avian flu-related revenue will not repeat, while Vifor is still dealing with generic competition and Behring has been hit by U.S. Medicare changes and policy shifts in China.
Peers are moving as well. Spanish plasma rival Grifols last week approved an initial public offering of a minority stake in its U.S. biopharma business to raise capital, reduce debt and fund investment, after saying in February it expected core earnings to rise by more than a quarter this year. 5
For now, CSL’s buyback gives the market a visible sign of balance-sheet strength. It does not settle the harder question. With full-year targets unchanged and several businesses still under strain, the next leg in the stock will depend less on financial engineering than on whether operating performance starts to turn.
